http://orcid.org/0000-0002-2045-0784
References
- Baker G, Matveychuk D, MacKenzie EM, et al. (2019). Attenuation of the effects of oxidative stress by the MAO-inhibiting antidepressant and carbonyl scavenger phenelzine. Chem Biol Interact 304:139–47.
- Culot M, Fabulas-da Costa A, Sevin E, et al. (2013). A simple method for assessing free brain/free plasma ratios using an in vitro model of the blood brain barrier. PLOS One 8:e80634.
- Di L, Breen C, Chambers R, et al. (2017). Industry perspective on contemporary protein-binding methodologies: considerations for regulatory drug–drug interaction and related guidelines on highly bound drugs. J Pharm Sci 106:3442–52.
- Di L, Umland JP, Chang G, et al. (2011). Species independence in brain tissue binding using brain homogenates. Drug Metab Dispos 39:1270–7.
- Di L, Umland JP, Trapa PE, Maurer TS. (2012). Impact of recovery on fraction unbound using equilibrium dialysis. J Pharm Sci 101:1327–35.
- de Lange EC. (2013). The mastermind approach to CNS drug therapy: translational prediction of human brain distribution, target site kinetics, and therapeutic effects. Fluids Barriers CNS 10:12.
- Fridén M, Bergström F, Wan H, et al. (2011). Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods. Drug Metab Dispos 39:353–62.
- Kalvass JC, Maurer TS, Pollack GM. (2007). Use of plasma and brain unbound fractions to assess the extent of brain distribution of 34 drugs: comparison of unbound concentration ratios to in vivo p-glycoprotein efflux ratios. Drug Metab Dispos 35:660–6.
- Kalvass JC, Phipps C, Jenkins GJ, Stuart P, et al. (2018). Mathematical and experimental validation of flux dialysis method: an improved approach to measure unbound fraction for compounds with high protein binding and other challenging properties. Drug Metab Dispos 46:458–69.
- Kielbasa W, Stratford RE Jr. (2012). Exploratory translational modeling approach in drug development to predict human brain pharmacokinetics and pharmacologically relevant clinical doses. Drug Metab Dispos 40:877–83.
- Liu X, Smith BJ, Chen C, et al. (2005). Use of a physiologically based pharmacokinetic model to study the time to reach brain equilibrium: an experimental analysis of the role of blood-brain barrier permeability, plasma protein binding, and brain tissue binding. J Pharmacol Exp Ther 313:1254–62.
- Liu X, Wright M, Hop CE. (2014). Rational use of plasma protein and tissue binding data in drug design. J Med Chem 57:8238–48.
- Longhi R, Corbioli S, Fontana S, et al. (2011). Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method. Drug Metab Dispos 39:312–21.
- Riccardi K, Cawley S, Yates PD, et al. (2015). Plasma protein binding of challenging compounds. J Pharm Sci 104:2627–36.
- Ryu S, Novak JJ, Patel R, et al. (2018). The impact of low temperature on fraction unbound for plasma and tissue. Biopharm Drug Dispos 39:437–42.
- Summerfield SG, Read K, Begley DJ, et al. (2007). Central nervous system drug disposition: the relationship between in situ brain permeability and brain free fraction. J Pharmacol Exp Ther 322:205–13.
- Ulrich S, Ricken R, Adli M. (2017). Tranylcypromine in mind (Part I): Review of pharmacology. Eur Neuropsychopharmacol 27:697–713.